Page last updated: 2024-11-07

n,n-dimethyl-3,3-diphenyl-1-methylallylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N-dimethyl-3,3-diphenyl-1-methylallylamine: component of Ketogin; RN given refers to parent cpd; synonym spasmolytic A29 refers to HCl; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122535
CHEMBL ID2260843
MeSH IDM0094482

Synonyms (13)

Synonym
einecs 249-909-6
29869-90-7
n,n-dimethyl-3,3-diphenyl-1-methylallylamine
a6fgc19uyp ,
n,n,1-trimethyl-3,3-diphenylallylamine
unii-a6fgc19uyp
CHEMBL2260843
a-29 lundbeck
allylamine, n,n,1-trimethyl-3,3-diphenyl-
3-buten-2-amine, n,n-dimethyl-4,4-diphenyl-
Q27273694
DTXSID20903625
noname_4328

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery."( Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1981
)
0.26

Bioavailability

ExcerptReferenceRelevance
"90 (SD) and the mean relative bioavailability of the mixture was slightly above 100%."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
"The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery."( Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
Anderson, P; Arnér, S; Bondesson, U; Boréus, LO; Hartvig, P, 1981
)
0.26

Dosage Studied

ExcerptRelevanceReference
" The patients were six days in hospital and were dosed two days with tablets, two days with mixture and finally another two days with tablets."( Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Kjaer, M; Nielsen, H, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]